What Does CAR T-Cell Therapy Mean?

CAR stands for chimeric antigen receptor. Chimeric means built from parts of different sources. The receptor is a built protein. One end grips a target on the cancer cell. The other end is the switch a T cell uses to turn itself on.

T cells are the immune system's attack cells. In many blood cancers, they simply do not see the tumor. CAR T-cell therapy fixes that. It installs a receptor that cannot miss the target.

The target matters. For lymphoma and leukemia, the target is CD19. That is a protein on the surface of B cells. For multiple myeloma, the target is BCMA, short for B-cell maturation antigen. The CARVYKTI label calls it a BCMA-directed autologous T cell therapy. Autologous means the cells came from you.

The National Cancer Institute lays out the steps. Blood is drawn and the T cells are pulled out. Those T cells are engineered to carry the CAR. They are then grown, or expanded, until there are hundreds of millions. Then they go back in by vein.

NCI puts the whole process at about 3 to 5 weeks.

That gap is a real planning problem, not a footnote. The cancer can grow while the cells are being made. Ask what bridging treatment covers those weeks. Ask what happens if the batch fails and has to be made again.

A few days before the infusion, you get chemotherapy. Its job is not to kill the cancer. Its job is to clear space so the new cells can grow.

The CARVYKTI label sets out the recipe: cyclophosphamide and fludarabine, both by vein, both daily for 3 days, at amounts the transplant pharmacy calculates from your body size.

Cytokine release syndrome, or CRS. When the new cells switch on, they release cytokines. Cytokines are immune signals. Too many at once cause fever, low blood pressure, and low oxygen. NCI names the drug: tocilizumab, sold as Actemra. It blocks a cytokine called IL-6. Steroids are used too.

Nerve and brain effects, often called ICANS. Signs include confusion, trouble finding words, tremor, changed handwriting, sleepiness, or seizures. NCI names steroids as the first treatment. If steroids fail, anakinra, sold as Kineret, may be used.

Both are usually reversible when caught early. That is the entire reason for the monitoring rules below.

For years, CAR T therapy ran under a Risk Evaluation and Mitigation Strategy, or REMS. It required that hospitals and clinics giving these products be specially certified. They also had to keep tocilizumab on site, ready at once.

On June 26, 2025, the FDA dropped the REMS for six of these products. They are Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), and Yescarta (axicabtagene ciloleucel).

Labeling changed at the same time, and the new numbers are shorter than the old ones:

• Stay near a health care facility for at least 2 weeks after the infusion.
• Do not drive for 2 weeks after the infusion.
• Be watched for at least 2 weeks. That includes daily checks for at least 1 week.

The boxed warning for CRS and nerve effects stayed. Dropping the REMS cut paperwork for hospitals. It did not cut the risk.

In plain terms, you need three things for those 2 weeks. A caregiver who can stay with you. A place to sleep near the center. Someone else to drive.

The CARVYKTI label carries several boxed warnings. CRS. Nerve and brain effects. A severe immune overreaction called HLH, or macrophage activation syndrome. Long-lasting low blood counts, known as cytopenia. And new blood cancers caused by the treatment. In October 2025 the FDA added one more: immune effector cell-associated enterocolitis, a severe swelling of the gut.

Two of those need unpacking. Cytopenia here means blood counts that stay low for weeks or months. That raises the risk of infection and bleeding long after you go home. New blood cancers can arise from the treatment itself. That is why follow-up runs for years.

Boxed warnings differ by product. Ask for the label of the exact product you will get, not a general handout.

NCI lists approvals across six diseases. B-cell acute lymphoblastic leukemia, in children and adults. Diffuse large B-cell lymphoma. Follicular lymphoma. Mantle cell lymphoma. Chronic lymphocytic leukemia. And multiple myeloma.

Approvals are written by line of therapy, and those lines have moved. Take CARVYKTI. It is now approved for adults with relapsed or refractory multiple myeloma. They must have had at least 1 prior line of therapy. That line must include a proteasome inhibitor and an immune-modulating drug. They must also be refractory to lenalidomide. Ask which prior treatments your own approval requires. That is what decides coverage.

In the first 2 weeks after infusion, do not wait to see if these pass:

• Call 911 or go to an emergency department for a seizure, fainting, breathing that is fast or hard, or someone you cannot wake properly. Severe CRS and severe neurologic toxicity are treated in hours, not days.
• Any fever — call the 24-hour number now, or go to an emergency department if nobody answers. It is the most common first sign of CRS, and it can equally be the only sign of a serious infection. Do not take a fever reducer first.
• Dizziness or a racing heart.
• Confusion, slurred speech, trouble naming objects, or odd sleepiness.
• Tremor, or handwriting that suddenly looks different.
• Severe diarrhea or belly pain.

The handwriting item is not folklore. Many centers ask patients to write the same sentence each day. A change there can show up before anything else does.

https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor

https://www.fda.gov/media/156560/download

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/carvykti